{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=NASH&page=18",
    "query": {
      "condition": "NASH",
      "page": 18
    },
    "page_size": 10
  },
  "pagination": {
    "page": 18,
    "page_size": 10,
    "total_count": 586,
    "total_pages": 59,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=NASH&page=19&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=NASH&page=17&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-21T17:39:46.661Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03744182",
      "title": "A Study of Multiple Doses of HM15211(Efocipegtrutide) in Obese Subjects With NAFLD",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "NAFLD"
      ],
      "interventions": [
        {
          "name": "HM15211",
          "type": "DRUG"
        },
        {
          "name": "Placebo of HM15211",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hanmi Pharmaceutical Company Limited",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 66,
      "start_date": "2018-11-01",
      "completion_date": "2020-03-18",
      "has_results": true,
      "last_update_posted_date": "2025-01-27",
      "last_synced_at": "2026-10-21T17:39:46.661Z",
      "location_count": 1,
      "location_summary": "Chula Vista, California",
      "locations": [
        {
          "city": "Chula Vista",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03744182"
    },
    {
      "nct_id": "NCT06355310",
      "title": "Mechanisms of SGLT2 Inhibition in Pediatric Steatotic Liver Disease",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Non-Alcoholic Fatty Liver Disease"
      ],
      "interventions": [
        {
          "name": "Empagliflozin 10 MG",
          "type": "DRUG"
        },
        {
          "name": "Placebo Oral Tablet",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Justin Ryder",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "16 Years",
        "maximum_age": "20 Years",
        "sex": "ALL",
        "summary": "16 Years to 20 Years"
      },
      "enrollment_count": 40,
      "start_date": "2025-04-10",
      "completion_date": "2028-02-01",
      "has_results": false,
      "last_update_posted_date": "2026-01-21",
      "last_synced_at": "2026-10-21T17:39:46.661Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06355310"
    },
    {
      "nct_id": "NCT03187496",
      "title": "Drug-drug Interaction Study Between EDP-305, Midazolam, Caffeine and Rosuvastatin in Healthy Volunteers.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "NASH"
      ],
      "interventions": [
        {
          "name": "Midazolam",
          "type": "DRUG"
        },
        {
          "name": "Caffeine",
          "type": "DRUG"
        },
        {
          "name": "Rosuvastatin",
          "type": "DRUG"
        },
        {
          "name": "EDP-305",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Enanta Pharmaceuticals, Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 24,
      "start_date": "2017-05-11",
      "completion_date": "2017-06-14",
      "has_results": false,
      "last_update_posted_date": "2017-08-21",
      "last_synced_at": "2026-10-21T17:39:46.661Z",
      "location_count": 1,
      "location_summary": "Lenexa, Kansas",
      "locations": [
        {
          "city": "Lenexa",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03187496"
    },
    {
      "nct_id": "NCT00694746",
      "title": "Study of Fish Oil to Reduce ALT Levels in Adolescents",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Non-alcoholic Fatty Liver Disease",
        "Fatty Liver"
      ],
      "interventions": [
        {
          "name": "Omega-3-acid ethyl esters",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Boston University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "13 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "13 Years to 17 Years"
      },
      "enrollment_count": 3,
      "start_date": "2008-06",
      "completion_date": "2014-03",
      "has_results": false,
      "last_update_posted_date": "2016-01-29",
      "last_synced_at": "2026-10-21T17:39:46.661Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00694746"
    },
    {
      "nct_id": "NCT05430178",
      "title": "Metabolic Pathology of Pediatric NAFLD",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Nonalcoholic Fatty Liver",
        "Nonalcoholic Steatohepatitis",
        "Obesity"
      ],
      "interventions": [
        {
          "name": "Oral sugar tolerance test",
          "type": "OTHER"
        },
        {
          "name": "De novo lipogenesis test",
          "type": "OTHER"
        },
        {
          "name": "Gluconeogenesis test",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "University of Oklahoma",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "10 Years",
        "maximum_age": "20 Years",
        "sex": "ALL",
        "summary": "10 Years to 20 Years"
      },
      "enrollment_count": 100,
      "start_date": "2022-05-25",
      "completion_date": "2026-06",
      "has_results": false,
      "last_update_posted_date": "2024-03-06",
      "last_synced_at": "2026-10-21T17:39:46.661Z",
      "location_count": 1,
      "location_summary": "Oklahoma City, Oklahoma",
      "locations": [
        {
          "city": "Oklahoma City",
          "state": "Oklahoma"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05430178"
    },
    {
      "nct_id": "NCT03696797",
      "title": "Iron Reduction for the Treatment of Diabetes and Nonalcoholic Fatty Liver Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Iron",
        "Diabetes",
        "Nonalcoholic Fatty Liver"
      ],
      "interventions": [
        {
          "name": "Blood Donation",
          "type": "PROCEDURE"
        },
        {
          "name": "Sham Blood Donation",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE"
      ],
      "sponsor": "Wake Forest University Health Sciences",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "40 Years to 75 Years"
      },
      "enrollment_count": 132,
      "start_date": "2019-05-03",
      "completion_date": "2025-01-03",
      "has_results": true,
      "last_update_posted_date": "2026-06-09",
      "last_synced_at": "2026-10-21T17:39:46.661Z",
      "location_count": 2,
      "location_summary": "Chapel Hill, North Carolina • Winston-Salem, North Carolina",
      "locations": [
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        },
        {
          "city": "Winston-Salem",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03696797"
    },
    {
      "nct_id": "NCT04480710",
      "title": "A Study of CRV431 Dosed Once Daily in NASH Induced F2 and F3 Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "NASH - Nonalcoholic Steatohepatitis",
        "Fibrosis, Liver",
        "NAFLD - Nonalcoholic Fatty Liver Disease"
      ],
      "interventions": [
        {
          "name": "CRV431 75mg",
          "type": "DRUG"
        },
        {
          "name": "Placebo (1 softgel)",
          "type": "DRUG"
        },
        {
          "name": "CRV431 225mg",
          "type": "DRUG"
        },
        {
          "name": "Placebo (3 softgels)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hepion Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 47,
      "start_date": "2020-06-23",
      "completion_date": "2021-10-30",
      "has_results": true,
      "last_update_posted_date": "2022-07-15",
      "last_synced_at": "2026-10-21T17:39:46.661Z",
      "location_count": 9,
      "location_summary": "Orange, California • Poway, California • Miami, Florida + 5 more",
      "locations": [
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Poway",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Port Orange",
          "state": "Florida"
        },
        {
          "city": "Sarasota",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04480710"
    },
    {
      "nct_id": "NCT04336618",
      "title": "Multi-Parametric MRI Assessment of the Liver in the Dallas-FortWorth Metroplex Population",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Non-Alcoholic Fatty Liver Disease"
      ],
      "interventions": [
        {
          "name": "Liver MultiScan",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Perspectum",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 67,
      "start_date": "2020-08-03",
      "completion_date": "2022-09-27",
      "has_results": false,
      "last_update_posted_date": "2023-12-22",
      "last_synced_at": "2026-10-21T17:39:46.661Z",
      "location_count": 1,
      "location_summary": "Dallas, Texas",
      "locations": [
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04336618"
    },
    {
      "nct_id": "NCT00736385",
      "title": "Metformin for the Treatment of Nonalcoholic Fatty Liver Disease (NAFLD)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Fatty Liver"
      ],
      "interventions": [
        {
          "name": "Glucophage (Metformin)",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Duke University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 11,
      "start_date": "2009-04",
      "completion_date": "2012-12",
      "has_results": true,
      "last_update_posted_date": "2024-01-26",
      "last_synced_at": "2026-10-21T17:39:46.661Z",
      "location_count": 1,
      "location_summary": "Durham, North Carolina",
      "locations": [
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00736385"
    },
    {
      "nct_id": "NCT02654002",
      "title": "Study in Healthy Volunteers to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GS-9674 (Cilofexor), and the Effect of Food on GS-9674 Pharmacokinetics and Pharmacodynamics",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Nonalcoholic Steatohepatitis (NASH)"
      ],
      "interventions": [
        {
          "name": "Cilofexor",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Gilead Sciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "18 Years to 45 Years"
      },
      "enrollment_count": 120,
      "start_date": "2016-01-20",
      "completion_date": "2016-07-14",
      "has_results": true,
      "last_update_posted_date": "2020-10-12",
      "last_synced_at": "2026-10-21T17:39:46.661Z",
      "location_count": 1,
      "location_summary": "Miami, Florida",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02654002"
    }
  ]
}